These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11829 related articles for article (PubMed ID: 12444803)

  • 1. Tumor vaccines: a role in preventing recurrence in melanoma?
    Sabel MS; Sondak VK
    Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
    Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA; Sondak VK
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
    Schadendorf D; Paschen A; Sun Y
    Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on active specific immunotherapy with melanoma vaccines.
    Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
    J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.
    Mocellin S; Rossi CR; Nitti D; Lise M; Marincola FM
    Biochim Biophys Acta; 2003 Dec; 1653(2):61-71. PubMed ID: 14643925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour cell-based vaccines for the treatment of melanoma.
    Hsueh EC
    BioDrugs; 2001; 15(11):713-20. PubMed ID: 11707146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines.
    Ralph SJ
    Am J Clin Dermatol; 2007; 8(3):123-41. PubMed ID: 17492842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based cancer vaccines.
    Machiels JP; van Baren N; Marchand M
    Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
    Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma vaccines: what we know so far.
    Bystryn JC; Reynolds SR
    Oncology (Williston Park); 2005 Jan; 19(1):97-108; discussion 108, 111-2, 115. PubMed ID: 15743154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 592.